Dopamine is both high and low in schizophrenia, just in different parts of the brain. Deep subcortical regions involved in reward and emotion have too much dopamine activity, while the prefrontal cortex, the area responsible for planning, motivation, and working memory, has too little. This dual imbalance is known as the revised dopamine hypothesis, and it explains why schizophrenia produces two very different sets of symptoms.
High Dopamine in Deeper Brain Regions
The mesolimbic pathway, a dopamine circuit that runs from the midbrain to a structure called the nucleus accumbens, is overactive in schizophrenia. This excess dopamine overstimulates a specific type of receptor (called D2), and the result is what clinicians call positive symptoms: hallucinations, delusions, and disorganized thinking. These aren’t “positive” in the good sense. They’re experiences added on top of normal perception, things a person sees, hears, or believes that aren’t grounded in reality.
Brain imaging studies have confirmed that the largest dopamine abnormality in schizophrenia is an increase in presynaptic dopamine activity, meaning the neurons in the striatum are producing and releasing more dopamine than normal. A meta-analysis of imaging studies found that elevated dopamine synthesis capacity, higher baseline dopamine levels, and greater dopamine release in the striatum are the most consistent biological findings across schizophrenia patients. Researchers can now measure this using PET scans that track how quickly the brain converts a tracer into dopamine, and those scans reliably show increased synthesis in striatal regions.
Low Dopamine in the Prefrontal Cortex
While deeper brain areas are flooded with dopamine, the prefrontal cortex is starved of it. This part of the brain handles executive function: planning ahead, staying motivated, holding information in working memory, and engaging in fluid conversation. When dopamine signaling drops here, the result is negative symptoms, including flat emotional responses, lack of motivation, social withdrawal, and difficulty producing speech. These symptoms are often harder to treat and can be more disabling day to day than hallucinations.
The prefrontal cortex is uniquely vulnerable to dopamine fluctuations because it lacks the efficient recycling system that other brain regions use. In the striatum, specialized transporter proteins quickly vacuum up released dopamine and repackage it. The prefrontal cortex has far fewer of these transporters, so it relies more heavily on an enzyme called COMT to break dopamine down after it’s released. That makes dopamine levels in this region especially sensitive to anything that speeds up COMT activity.
A Genetic Link: The COMT Gene
One well-studied genetic factor involves a variation in the COMT gene. Everyone carries one of two versions at a key position: either a Val or a Met variant. The Val version produces an enzyme that is up to four times more active than the Met version, meaning it breaks down prefrontal dopamine much faster. Research published in the Proceedings of the National Academy of Sciences found that people carrying the Val variant performed worse on tasks requiring prefrontal function, like working memory, and showed less efficient prefrontal brain activity during those tasks.
This matters for schizophrenia because the Val variant, by depleting prefrontal dopamine more aggressively, appears to slightly increase risk for the disorder. It doesn’t cause schizophrenia on its own, but it adds an extra burden on a brain region that may already be underperforming due to other genetic or environmental factors. Studies in mice missing the COMT gene entirely showed increased dopamine levels only in the prefrontal cortex, not the striatum, and those mice actually performed better on memory tasks. This confirms that COMT’s effects on dopamine are specific to the prefrontal cortex.
How Glutamate Ties the Two Problems Together
The high-dopamine and low-dopamine problems aren’t independent. They may share a common upstream cause involving glutamate, the brain’s main excitatory chemical messenger. One leading theory proposes that certain receptors on inhibitory brain cells in the cortex are defective in schizophrenia. When these inhibitory cells don’t work properly, glutamate-releasing neurons that project down to the midbrain become overactive. This overstimulates dopamine neurons in the mesolimbic pathway, flooding the striatum with excess dopamine.
At the same time, these overactive glutamate signals may overstimulate a separate set of inhibitory cells in a region called the ventral tegmental area. Those inhibitory cells then suppress the dopamine neurons that project up to the prefrontal cortex. The net result: too much dopamine in one circuit, too little in another, both traceable to the same glutamate malfunction.
How Medications Target This Imbalance
Most antipsychotic medications work by blocking D2 receptors in the striatum, reducing the impact of excess dopamine there. PET imaging studies have established that blocking between 65% and 80% of D2 receptors produces the best therapeutic effect for positive symptoms like hallucinations and delusions. Below 65%, the medication tends to be ineffective. Above 80%, the risk of movement-related side effects (stiffness, tremors, restlessness) rises sharply. This leaves a narrow therapeutic window of about 60% to 85% occupancy.
The challenge is that traditional antipsychotics block D2 receptors everywhere, including the prefrontal cortex where dopamine is already too low. This can worsen negative symptoms like apathy and cognitive difficulties, or at best leave them unchanged.
Newer approaches try to work with the imbalance rather than blanketing the whole brain. One medication, aripiprazole, acts as what pharmacologists call an adaptive modulator. In brain areas where dopamine is already high, it behaves mostly like a blocker, reducing D2 activation. In areas where dopamine is low, it behaves more like a mild stimulator, partially activating D2 receptors instead of shutting them down entirely. Its behavior literally shifts depending on how much dopamine is present in each region. This makes it less likely to cause the movement side effects associated with full D2 blockers, because it preserves a baseline level of dopamine signaling rather than suppressing it completely.
Why This Matters for Understanding Symptoms
The dual nature of dopamine dysfunction explains something that puzzles many people about schizophrenia: how the same person can experience vivid hallucinations (a sign of overactivity) while also struggling to feel pleasure, stay motivated, or hold a conversation (signs of underactivity). These aren’t contradictory. They reflect two sides of the same imbalance playing out in different brain circuits.
It also explains why treatment is so difficult to get right. Turning down dopamine broadly with older medications can quiet the hallucinations but deepen the motivational and cognitive problems. The goal of current and emerging treatments is to correct each circuit independently, dampening excess dopamine in the mesolimbic pathway while preserving or boosting it in the prefrontal cortex. That balancing act remains one of the central challenges in schizophrenia treatment.